Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C 21

Drug Profile

C 21

Alternative Names: C21; Compound 21 - Vicore Pharma; VP 01

Latest Information Update: 16 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vicore Pharma
  • Class Antifibrotics; Antihyperglycaemics; Small molecules; Vascular disorder therapies
  • Mechanism of Action Angiotensin type 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Raynaud's disease
  • Phase I Fibrosis
  • Preclinical Diabetes mellitus; Dupuytren's contracture

Most Recent Events

  • 13 Dec 2019 Phase-II clinical trials in Raynaud's disease in United Kingdom (PO) (EudraCT019-003203-35)
  • 22 Apr 2019 Vicore Pharma terminates phase II trial in Idiopathic pulmonary fibrosis (In adults, In the elderly) in the United Kingdom (PO) (EudraCT2017-004923-63)
  • 13 Jul 2018 Pharmacodynamics and adverse events data from a phase I extension trial in idiopathic pulmonary fibrosis released by Vicore Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top